placebo + levodopa

This combination refers to the control arm used in clinical trials sponsored by GSK, specifically in studies evaluating ropinirole prolonged release (Requip XL) for advanced Parkinson's disease. In this context, patients maintain a stable dose of levodopa, the standard-of-care dopamine precursor, while receiving an inactive placebo. Levodopa is a small molecule drug that crosses the blood-brain barrier and is converted into dopamine, helping to manage motor symptoms such as bradykinesia and rigidity. The placebo component serves as a baseline to measure the incremental benefit and safety of adding a dopamine agonist like ropinirole to existing levodopa therapy, particularly in patients experiencing 'off-time' as their medications wear off.

Other names

placebo/L-dopaplacebo/levodopa